<DOC>
	<DOC>NCT00334581</DOC>
	<brief_summary>Primary objective: - To determine if irbesartan 300mg is better than 150mg in protecting the kidneys in hypertensive patients with diabetes and microalbuminuria. Secondary objectives: - To determine how well irbesartan 300mg is tolerated versus 150mg - To determine the percentage of patients reaching the blood pressure target of 130/80 mmHg</brief_summary>
	<brief_title>Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria</brief_title>
	<detailed_description />
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Hypertensive patients, treated or untreated, with type 2 diabetes and urinary albumin excretion rate 20200ug/min. Blood pressure of &lt; 180/110mmHg at baseline Normal serum creatinine Type 1 diabetes Use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers in the 5 weeks before recruitment Pregnant or lactating women Severe hypertension Overt nephropathy Allergy to study drug The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>